Drugs / TYK-00540
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06246071 | Jan 2024 → Dec 2026 expected | — | TYK Medicines, Inc | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07104643 | Aug 2025 → Nov 2026 expected | castration-resistant prostate carcinoma | TYK Medicines, Inc | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06950086 | Jan 2024 → Sep 2026 overdue | hormone receptor-positive breast cancer | TYK Medicines, Inc | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TYK-00540 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06950086 ↗ |
| Action | Inhibit | “CDK2/4/6 Inhibitor” NCT06950086 ↗ |
| Route | Oral | “administered orally” NCT06246071 ↗ |
| Target | CDK2 | “CDK2/4/6 Inhibitor” NCT06950086 ↗ |